TABLE 3.
Detailed data on screening results, comparing LBC results and histological results according to high-risk-HPV test results
| Histological findings | Observed resultsa |
Verification bias-adjusted results |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Normal (Pap I or II) | ASCUS or AGC (Pap IIw) | ASC-H or AGUS (Pap III) | LSIL or HSIL (Pap IIID) | HSIL, CIS, or micro (Pap IVa or IVb) | Total | Normal (Pap I, II, or IIw) | Low grade (Pap III or IIID) | High grade, CIS, or micro (Pap IVa or IVb) | Total | |
| Histological data not available (no.) | ||||||||||
| Total | 8,582 | 236 | 6 | 21 | 3 | 8,848 | ||||
| AHPV test positive | 80 | 10 | 0 | 15 | 3 | 108 | ||||
| HC2 test positive | 119 | 10 | 0 | 17 | 3 | 149 | ||||
| <CIN2 (no.) | ||||||||||
| Total | 343 | 44 | 23 | 94 | 9 | 513 | 9,189.4 | 140.2 | 9.7 | 9,339.3 |
| AHPV test positive | 192 | 24 | 7 | 45 | 6 | 274 | 294.8 | 64.4 | 6.7 | 365.9 |
| HC2 test positive | 245 | 28 | 7 | 59 | 6 | 345 | 389.9 | 79.4 | 6.7 | 476.0 |
| CIN2 (no.) | ||||||||||
| Total | 26 | 5 | 2 | 8 | 6 | 47 | 41.5 | 11.6 | 6.6 | 59.7 |
| AHPV test positive | 23 | 5 | 2 | 6 | 6 | 42 | 34.8 | 9.4 | 6.6 | 50.8 |
| HC2 test positive | 23 | 5 | 2 | 7 | 6 | 43 | 35.0 | 10.5 | 6.6 | 52.1 |
| CIN3+ (no.) | ||||||||||
| Total | 20 | 1 | 2 | 5 | 15 | 43 | 26.1 | 9.1 | 16.7 | 52.0 |
| AHPV test positive | 18 | 1 | 1 | 5 | 15 | 40 | 23.4 | 7.1 | 16.7 | 47.2 |
| HC2 test positive | 20 | 1 | 2 | 5 | 15 | 43 | 26.1 | 9.1 | 16.7 | 52.0 |
| Total | ||||||||||
| Total no. | 8,971 | 286 | 33 | 128 | 33 | 9,451 | 9,257 | 161 | 33 | 9,451.0 |
| % AHPV test positive | 3.5 | 13.9 | 30.3 | 55.5 | 90.9 | 4.9 | 3.8 | 5.0 | 90.9 | 4.9 |
| % HC2 test positive | 4.5 | 15.4 | 33.3 | 68.8 | 90.9 | 6.1 | 4.9 | 6.1 | 90.9 | 6.1 |
a
AGC, atypical glandular cells; AGUS, atypical glandular cells of undetermined significance; CIS, carcinoma in situ; micro, microinvasive carcinoma.